Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
June 28, 2021 10:13 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast...
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020
December 03, 2020 10:20 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis
October 14, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Two clinical trial sites activated in Turkey, with patient screening initiatedFollows activation of six clinical sites in Hungary and dosing of first eight patientsTopline data expected in Q2 2021 ...
Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada
September 30, 2020 10:00 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
August 31, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange
July 20, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosisExchange of $6.9 million principal amount of...
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
July 08, 2020 10:00 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
APOLLOMICS（冠科美博）宣布启动C-MET抑制剂APL-101的II期全球多中心临床试验SPARTA
May 21, 2020 07:10 ET
|
Apollomics, Inc.
评估不分肿瘤类型的各种MET失调；聚焦MET 14号外显子跳跃突变的非小细胞肺癌及有MET扩增和融合的肿瘤，包括非小细胞肺癌，多形性胶质母细胞瘤及其他肿瘤 中国杭州市和美国福斯特市报道, May 21, 2020 (GLOBE NEWSWIRE) -- Apollomics,...
Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101
May 21, 2020 07:10 ET
|
Apollomics, Inc.
- Trial will evaluate diverse MET dysregulations across broad tumor types - - Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with...
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
May 07, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...